Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/β-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: A hellenic Cooperative Oncology Group (HECOG) study

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2479-2486

  Bamias, Aristotelis ^a,e   Kyriakou, F ^a   Chorti, M ^b   Kavantzas, N ^a   Noni, A ^a   Kyroudi Voulgari, A ^a   Rontoyianni, D ^c   Kastritis, E ^a   Xiros, N ^a   Patsouris, E S ^a   Murray, S ^d   Tamvakis, N ^b   Dimopoulos, M A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SISMANOGLIO HOSPITAL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d METROPOLITAN HOSPITAL   (Greece)

^e NONE   (Greece)

Author keywords

Bladder cancer; CD105; COX 2; MVD; Catenin

Indexed keywords

BETA CATENIN; CARBOPLATIN; CYCLOOXYGENASE 2; KI 67 ANTIGEN; PACLITAXEL; PROTEIN P53; VASCULOTROPIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BIOACCUMULATION; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DENSITY; DISEASE DURATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MICROVESSEL DENSITY; MULTIPLE CYCLE TREATMENT; PARAMETER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER;

EID: 48849100188     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Herr HW: Uncertainty and outcome in invasive bladder cancer. Urol Oncol 2: 92-95, 1996.
2. Bamias A, Deliveliotis Ch, Aravantinos G et al: Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic Cooperative Oncology Group. J Urol 171: 1467-1470, 2004.
3. Sarkis A, Bajorin DF, Reuter V et al: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant chemotherapy. J Clin Oncol 13: 1384-1390, 1995.
4. Protopapas A, Diakomanolis E, Bamias A et al: The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. Eur J Gynaecol Oncol 25: 225-229, 2004.
5. Secord AA, Sayer R, Snyder S et al: The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecol Oncol 94: 74-79, 2004.
6. Vane JR, Bakhle YS and Bolting RM: Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120, 1998.
7. Fujiwaki R, Iida K, Kanasaki H et al: Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 33: 213-219, 2002.
8. Sweeney CJ, Marshall MS, Barnard DS et al: Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detection and Prevention 26: 238-244, 2002.
9. Kirschenbaum A, Klausner AP, Lee R et al: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human prostate. Urology 56: 671-676, 2000.
10. Mohhamed SI, Benhett PF, Craig BA et al: Effects of the cyclooxygenase inhibitor, Piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 62: 356-358, 2002.
11. Friedrich MG, Toma MI, Petri S and Huland H: Cyclooxygenase-2 promotes angiogenesis in pTa/Tl urothelial bladder carcinoma but does not predict recurrence. BJU Int 92: 389-392, 2003.
12. Uefuji K, Ichikura T and Mochizucki H: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 6: 135-138, 2000.
13. Dannenberg AJ and Zakim D: Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. Semin Oncol 26: 499-504, 1999.
14. Koki AT and Masferrer JL: Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 9: 28-35, 2002.
15. Kawamoto T, Shoda J, Asano T et al: Expression of cyclooxygenase-2 in the subserosal layer correlates with post surgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int J Cancer 98: 427-434, 2002.
16. Ali-Fehmi R, Che M, Khalifeh I et al: The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 98: 1423-1429, 2003.
17. Khuri FR, Wu H, Lee JJ et al: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7: 861-867, 2001.
18. Dannenberg AJ, Altorki NK, Boyle JO et al: Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncology 2: 544-551, 2001.
19. Grossman HB: Selective COX-2 inhibitors as chemopreventive and therapeutic agents. Drugs Today 39: 203-211, 2003.
20. Shirahama T, Arima J, Akiba S et al: Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92: 188-193, 2001.
21. Sheehy OE, Zhao SZ, Raymoundo AL et al: Celecoxib associated with reduced risk of superficial bladder cancer (SBC) recurrence. Proc ASCO 22: 383 (abstr 1540), 2003.
22. Kim SI, Kwon SM, Kim YS and Hong SJ: Association of cyclooxygenase-2 expression with prognosis of stage I grade 3 bladder cancer. Urology 60: 816-821, 2002.
23. Shariat SF, Matsumoto K, Kim J et al: Correlation of cyclooxy genase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol 170: 985-989, 2003.
24. Bamias A, Deliveliotis Ch, Fountzilas G et al: Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol 22: 2150-2154, 2004.
25. McDermott U, Longley DB and Johnston PG: Molecular and biochemical markers in colorectal cancer. Ann Oncol 10: 235-245, 2002.
26. Zhu X, Kanai Y, Saito A et al: Aberrant expression of β-catenin and mutation of exon 3 of the β-catenin gene in renal and urothelial carcinomas. Pathol Int 50: 945-952, 2000.
27. Jaeger M, Weidner N, Chew K et al: Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 154: 69-71, 1995.
28. Fonsatti E and Maio M: Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transi Med 2: 1-7, 2004.
29. Tanaka F, Otake Y, Yanagihara K et al: Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7: 3410-3415, 2001.
30. Bocci G, Nikolaou KC and Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62: 6938-6943, 2002.
31. Giatromanolaki A, Stathopoulos GP, Koukourakis MI et al: Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin monotherapy. Am J Clin Oncol 24: 222-226, 2001.
32. Paradiso A, Mangia A, Chiriatti A et al: Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 16(Suppl 4): 14-19, 2005.
33. SS Seo, Song YS, Kang D et al: Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol 92: 927-935, 2006.
34. Buchanan FG and DuBois RN: Connecting COX-2 and Wnt in cancer. Cancer Cell 8: 6-8, 2006.
35. Lee K and Jeong S: β-Catenin stabilizes cyclooxygenase-2 mRNA by interacting with AU-rich elements of 3'-UTR. Nucl Acids Res 34: 5705-5714, 2006.
36. Tatsuguchi A, Kishida T, Fujimori S et al: Differential expression of cyclo-oxygenase-2 and nuclear beta-catein in colorectal cancer tiisue. Aliment Pharmacol Ther 26 (Suppl 4): 153-159, 2006.
37. Calviello G, Resci F, Serini S et al: Docosahexanoic acid induces proteasome-dependent degradation of {beta}-catenin, down-regulation of surviving and apoptosis in human colorectal cells not expressing COX-2. Carcinogenesis (Epub ahead of print).